Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) shares are -82.33% down in the year-to-date (YTD) period and have moved -6.87% or -$0.2 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +12.92% lower. Comparatively, the stock is -95.04% down YTD and -33.58% over the trailing 3-month period. If we look at the shorter duration, its week performance is 3.04% and -6.87% over the month.
1 analysts offering the recommendations for the stock have a consensus rating of 2.00 to suggest that the SONN stock is a “Moderate Buy. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $2.71. The forecasts give the Sonnet BioTherapeutics Holdings Inc. stock a price target range of $7.00 on the higher side while at least one analyst think the stock could plunge to a low of $7.00. The two limits represent an upside potential of 61.29% or 61.29%.
Analysts estimate the earnings to decrease -207.70% in the current quarter to $0, up from the -$8.84 reported in the same quarter a year ago. Wall Street estimates earnings per share to be at an average of -$2.96 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 1 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 5,000 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Signet Jewelers Limited (NYSE:SIG), on the other hand, is trading around $16.80 with a market cap of $879.48M and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $9.00 and spell out a less modest performance – a -86.67% return. Some analysts are even forecasting -$2.09 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Signet Jewelers Limited (SIG) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
SIG’s operating margin was negative on the trailing 12 months basis, remaining steady at -2.50%, while the operating expenses over the recent quarter were at $504.7 million. This represented a 40.77% of the company’s total revenues which amounted $852.1 million. With this in place, we can see that the company’s diluted EPS declined -$3.96 on the year-over-year period, shrinking to -$0.35 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Jul 2020), the total assets figure advanced to $6.88 billion from $6.3 billion over the previous quarter. The cash flow from operating activities totaled -$7.6 million, significantly lower than the $105.4 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$15.3 million.
Insiders have transacted a total of 127 times at Signet Jewelers Limited over the last 6 months, with insider purchases undertaken 76 times and accounting for 1,116,385 shares. Insider sales totaled 51,072 shares over the same period, with these deals completed in 51 transactions. Looking at these numbers, we realize that net purchases over that period are 25.0 shares. Insiders now hold a total of 1.69M shares after the latest sales, with 197.50% net shares purchased.
Insiders own 3.10% of the company shares with a share float percentage of 50.91M. Investors are also buoyed by the number of investors in a company, with Signet Jewelers Limited having a total of 291 institutions that hold shares in the company.